NCT05048680 Effect of Hypoxic Conditioning on Cerebrovascular Health in the Elderly
| NCT ID | NCT05048680 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Grenoble |
| Condition | Hypoxia |
| Study Type | INTERVENTIONAL |
| Enrollment | 64 participants |
| Start Date | 2021-10-13 |
| Primary Completion | 2024-03-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 64 participants in total. It began in 2021-10-13 with a primary completion date of 2024-03-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In line with the ever-growing aging of Western populations, the development of preventive strategies to slow down the effects of aging on cardiovascular health represents a major challenge in order to preserve functional capacities and a sufficient quality of life in the elderly. The alteration of vascular function (at the cerebral and systemic level) with aging is an important feature in the clinical picture including a decrease in physical and cognitive capacities. Although physical activity is recognized as an essential means of combating the effects of aging, optimizing its effects by defining the most effective strategies of practice remains a key objective. Offering alternative interventions to exercise training is also necessary for people who are unwilling or unable to engage in a physical activity program. In this context, hypoxic conditioning, alone or in conjunction with rehabilitative exercise training, is a new therapeutic modality with strong preclinical validity, in particular from a cardiovascular standpoint, and used in other pathologies to improve cardiovascular function and exercise performance and quality of life. Our aim is, therefore, to investigate the effect of hypoxic conditioning (alone or in conjunction with exercise training) on cerebrovascular health in the elderly.
Eligibility Criteria
Inclusion Criteria: * 60 to 80 years of age; * Being physically inactive (less than 150 min/week of moderate to intense physical activity); * No chronic cardiovascular, respiratory, metabolic or neuromuscular disease counterindicating an exercise training or hypoxic conditioning program; * Health coverage; * Being able to provide written fully informed consent. Exclusion Criteria: * Body-mass index \>30 kg/m2; * Smoking (\> cigarettes/day); * Alcohol use (\> 10g/day); * Mental disorder or history of mental disorder; * Beta-blockade treatment; * Inability or refusal to provide informed consent; * No health coverage * People exceeding the annual ceiling of allowances received as a result of their participation in other clinical trials; * People deprived of freedom by judicial or administrative decision; * People subject to legal protection, who cannot be included in clinical trials.
Contact & Investigator
Stéphane Doutreleau, MD, PhD
PRINCIPAL INVESTIGATOR
CHU Grenoble Alpes, Grenoble Alpes University
Frequently Asked Questions
Who can join the NCT05048680 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, up to 80 Years, studying Hypoxia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05048680 currently recruiting?
Yes, NCT05048680 is actively recruiting participants. Contact the research team at sdoutreleau@chu-grenoble.fr for enrollment information.
Where is the NCT05048680 trial being conducted?
This trial is being conducted at La Tronche, France.
Who is sponsoring the NCT05048680 clinical trial?
NCT05048680 is sponsored by University Hospital, Grenoble. The principal investigator is Stéphane Doutreleau, MD, PhD at CHU Grenoble Alpes, Grenoble Alpes University. The trial plans to enroll 64 participants.